Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma

Devalingam Mahalingam(The University of Texas at San Antonio Health Science Center), Steffan T. Nawrocki(University of Arizona), Ernest Medina(The University of Texas at San Antonio Health Science Center), Jennifer S. Carew(University of Arizona), Pietro Taverna, Claudia M. Espitia(The University of Texas System), David J. Bearss(Unknown), Gavin Choy(SuperGen (United States)), Juan Esquivel(The University of Texas at San Antonio Health Science Center), Francis J. Giles(National University of Ireland), Kevin R. Kelly(Keck Hospital of USC)
British Journal of Cancer
October 20, 2011
10.1038/bjc.2011.426
Cited by 28

Related Papers

Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951
Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
|Clinical Cancer Research|2008|782
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
|Blood|2006|691
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:
|Cancer|2006|607
Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl–mediated drug resistance
|Blood|2007|485